Abstract
Background:
Interleukin-3 (IL-3) is an experimental agent used to ameliorate neutropenia in patients receiving chemotherapy. Arterial thrombotic episodes after use of IL-3 have not been reported previously.
Methods:
The case of a patient with Stage III adenocarcinoma of the breast who developed hypotension and acute cerebellar artery and superior mesenteric artery thrombosis after receiving chemotherapy and treatment with IL-3 is reported.
Results:
To the authors' knowledge, this is the first patient with arterial thrombosis reported after treatment with IL-3.
Conclusions:
Interleukin-3 may be associated with increased propensity for thrombosis.
MeSH terms
-
Acute Disease
-
Adenocarcinoma / drug therapy*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Breast Neoplasms / drug therapy*
-
Cerebellum / blood supply
-
Cyclophosphamide / administration & dosage
-
Doxorubicin / administration & dosage
-
Female
-
Fluorouracil / administration & dosage
-
Humans
-
Interleukin-3 / adverse effects*
-
Intracranial Embolism and Thrombosis / chemically induced
-
Leucovorin / administration & dosage
-
Mesenteric Artery, Superior
-
Middle Aged
-
Myeloproliferative Disorders / chemically induced
-
Myeloproliferative Disorders / prevention & control*
-
Thrombosis / chemically induced*
Substances
-
Interleukin-3
-
Doxorubicin
-
Cyclophosphamide
-
Leucovorin
-
Fluorouracil